Search Results 721-730 of 17671 for corticosteroid

  1. A Study of Copanlisib and Nivolumab in Treating Participants With Recurrent or Refractory Diffuse Large B-cell Lymphoma or Primary Mediastinal Large B-cell Lymphoma - Mayo Clinic

    ... corticosteroids, should be excluded; these include but are not limited to patients with a history of immune related neurologic disease, multiple sclerosis ...

  2. CC-4047 in Treating Patients With Myelofibrosis - Mayo Clinic

    More than 28 days since prior growth factors, cytotoxic chemotherapeutic agents (e.g., hydroxyurea or anagrelide), corticosteroids, or experimental drugs or ...

  3. A Study Comparing the Effectiveness of Tiotropium and Olodaterol in Fixed Dose Combination Over Tiotropium Alone in Reducing Moderate to Severe Wosening of Symptoms in Patients with Severe to Very Severe Chronic Obstructive Pulmonary Disease - Mayo Clinic

    ... corticosteroids and/or antibiotics and/or related hospitalization ... Treated with oral corticosteroid medication at unstable doses; Treated with ...

  4. Publications - Karissa N. Arca, M.D. - Mayo Clinic

    ... Corticosteroid Use. Headache. 2020 Sep; 60 (8):1558-1568 Epub 2020 July 10. View PubMed; Arca K, Reynolds J, Sands KA, Shiue HJ. Calcitonin Gene-Related ...

  5. A Study to Evaluate both the Efficacy and Safety Profile of CP-690,550 in Patients with Moderately to Severely Active Ulcerative Colitis - Mayo Clinic

    Corticosteroids (oral or intravenous). Azathioprine or 6 mercaptopurine (6 MP). Anti TNF therapy. Exclusion Criteria: Presence of indeterminate colitis ...

  6. Lenalidomide in Improving Immune Response to Vaccine Therapy in Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Monoclonal B Cell Lymphocytosis - Mayo Clinic

    ... corticosteroid therapy for an indication other than CLL/SLL will not be considered "prior treatment"; previous use of corticosteroids for treatment of ...

  7. Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen - Mayo Clinic

    corticosteroid treatment <=10 mg per day for these metastases for at least 4 weeks and have radiographically stable disease of brain lesions for at least 3 ...

  8. Safety and Activity of PolyPEPI1018 Plus Atezolizumab in Colorectal Cancer. - Mayo Clinic

    stable dose of insulin regimen are also eligible for this study. 7. Receiving systemic corticosteroids within one week prior to the first dose of study

  9. Ulcerative colitis - Symptoms and causes - Mayo Clinic

    Treatments may include anti-inflammatory drugs like corticosteroids and immune system suppressants. Certain targeted therapies directed against the immune ...

  10. Aliya™ Pulsed Electric Fields (PEF) Delivered Prior to Standard of Care Treatment for Advanced Cancer - Mayo Clinic

    trigger are permitted to enroll. - Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary ...